Cube Labs lists on Euronext Growth Milan Professional Segment

Mar 21 2023 - 09:00

• 7th listing of 2023 on Euronext Growth Milan

• Cube Labs brings the total number of companies listed on Euronext Growth Milan to 196

• 10th listing on Euronext in 2023

• Total placement volume of the offering equal to €4.1 million

Milan – 21 March 2023 – Borsa Italiana, part of the Euronext Group, today congratulates Cube Labs on its listing on the Professional Segment of Euronext Growth Milan.

Cube Labs is a venture builder specialising in project development in the Healthcare & Life Sciences sector. The company selects projects from promising early-stage R&D and contributes to their growth by setting up new companies, enabling innovation and turning pioneering science into healthcare solutions.

Cube Labs represents the seventh listing since the beginning of the year on Borsa Italiana’s market dedicated to small and medium-sized companies, and it brings the total number of firms currently listed on Euronext Growth Milan to 196.

In the placement phase, Cube Labs raised €4.1 million. The free float at the time of admission was 12.04% and the market capitalisation at IPO was €34.1 million.

Filippo Surace, CEO and Founder of Cube Labs, said: “The listing of Cube Labs on Euronext Growth Milan represents a historic moment, because today Italian academic research enters into the capital market with an innovative business model. Today's listing will enable Cube Labs to grow and establish a unique model based on the cutting-edge research and technologies developed by the companies in our portfolio. This is in the rapidly evolving Life Science sector, which represents the new frontier of healthcare in Italy and the world. We have received positive feedback from professional investors, indicating that our access to the stock market will support Cube Labs’ growth strategy, particularly at an international level. This includes leveraging our network in the academic world to create science companies in the biotech and medtech sectors through an innovative public-private technology transfer model. Our ultimate goal is to facilitate the commercial development of scientific research projects in markets with high growth potential.”

Download the pdf here